Sangamo BioSciences, Inc. in Race to Replace Chronic Drug Treatment With Gene Therapies

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

The Foster City, CA-based biopharmaceutical giant Gilead (NASDAQ: GILD) reaps about $8 billion a year from its daily drug regimens that keep the HIV virus in check. Gilead’s Bay area neighbor, San Rafael, CA-based BioMarin Pharmaceutical (NASDAQ: BMRN), earns nearly half a billion dollars annually from its pioneering drugs for rare disorders that would otherwise cripple or kill children. Despite those significant advances in medicine, rising companies such as Richmond, CA-based Sangamo BioSciences (NASDAQ: SGMO) think they can do much better. They’re trying to free patients from a lifetime of pills or infusions by giving them one-time doses of gene therapy.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC